|
EDMA
3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class.[1][2] It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring.[1][2] EDMA was first synthesized by Alexander Shulgin.[1] In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours.[1] According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects.[1] It has been found that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.[2] However, subsequent research found that EMDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA) with EC50 values of 117 nM for serotonin release, 325 nM for norepinephrine release, and 597 nM for dopamine release in rat brain synaptosomes.[3] Compared to MDMA, EDMA was about half as potent as a serotonin releaser, 4.5-fold less potent as a norepinephrine releaser, and 8-fold less potent as a dopamine releaser.[3] The activities of the individual enantiomers of EDMA have also been assessed.[3] See also
References
External links |
||||||||||||||||||||||||||||||||||||||||||
